Association between XRCC2 Arg188His Polymorphism and Breast Cancer Susceptibility: A Systematic Review and Meta-Analysis

Document Type : Systematic Review and Meta-analysis

Authors

1 Department of Medical Genetics, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.

2 Department of Surgery, Firoozgar Clinical Research Development Center (FCRDC), Iran University of Medical Sciences, Tehran, Iran.

3 Akbarabadi Cilinical Research Development Unit, Iran University of Medical Sciences, Tehran, Iran.

4 Preventative Gynecology Research Center, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

5 Department of Medical Laboratory Sciences, School of Paramedical Science, Shiraz University of Medical Sciences, Shiraz, Iran.

6 Department of Obstetrics and Gynecology, Firoozgar Hospital, Firoozgar Clinical Research Development Center (FCRDC), Iran University of Medical Sciences (IUMS), Tehran, Iran.

7 Department of Radiation Oncology, Firoozgar Hospital, Firoozgar Clinical Research Development Center (FCRDC), Iran University of Medical Sciences (IUMS), Tehran, Iran.

8 Student Research Committee, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.

9 Mother and Newborn Health Research Center, Shahid Sadoughi Hospital, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

10 Department of Radiology, Shahid Rahnemoon Hospital , School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

Abstract

Breast cancer is one of the most common cancers in the world and leading cause of cancer-related death among women. Several studies indicated that Arg188His (rs3218536) polymorphism of X-ray repair cross-complementing 2 (XRCC2) may be associated with breast cancer risk. However, this association remains ambiguous. Thus, we performed a meta-analysis to provide more precise conclusion on this issue. A comprehensive search in PubMed, Google Scholar and ISI Web of Science was performed to select all relevant studies. Odds ratios (OR) with corresponding 95% confidence intervals (CI) were applied to assess the strength of the relationships. A total of 17 studies with 5694 breast cancer cases and 6450 healthy subjects were identified. The pooled data revealed that XRCC2 Arg188His polymorphism was marginally with susceptibility to breast cancer globally under the heterozygote contrast (OR = 0.929, 95% CI = 0.873-0.987, p=0.018). Moreover, subgroup analysis by ethnicity revealed that this polymorphism was associated with breast cancer risk among Caucasians. On the whole, the present study demonstrates that the XRCC2 Arg188His polymorphism may contribute to an increased risk of breast cancer.

Keywords

Main Subjects


Volume 25, Issue 1
January 2024
Pages 43-55
  • Receive Date: 23 September 2023
  • Revise Date: 10 December 2023
  • Accept Date: 24 January 2024
  • First Publish Date: 24 January 2024